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Using multi-hub structures for international R&D: organizational inertia and 
the challenges of implementation 
 
Abstract: Over the last decade or so, multinational enterprises (MNEs) have shifted 
from centralised hub structures to multi-hub structures. While these new structures 
provide greater potential for cross-fertilization of technologies and access to location-
specific competences, promoting effective knowledge transfer within an MNE – 
especially in their R&D activities - presents significant managerial challenges. Using 
evidence collected on the R&D activities of MNEs in the pharmaceutical sector, this 
paper analyses the challenges associated with complexities of promoting and 
integrating knowledge flows in the face of inter-unit geographical, organizational and 
technological distance. MNEs are faced with organizational inertia that hinders 
efficient lateral communication and inter-unit knowledge transfer, and the evidence 
suggests that while socialization mechanisms help overcoming some of these 
bottlenecks, there remain a number of obstacles in optimising knowledge flows in 
physically and technologically dispersed R&D facilities. 
 
INTRODUCTION 
In a relatively short span of three decades, the extent, spread, motivation, location and 
nature of the overseas R&D activities of multinational firms (MNEs) has become 
incredibly complex. Some of these changes reflect the increasingly complex nature of 
MNE activities, as the nature of headquarters – subsidiary relationships have been re-
organised away from an ethnocentric, home country dominated structure, to a more 
widely distributed and complex network of knowledge flows between subsidiaries and 
headquarters in several locations. As recently as the 1970s, technology transfer was 
predominantly uni-directional from headquarters to overseas subsidiaries, and R&D 
primarily asset-exploiting in nature, incremental and associated with demand-driven 
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innovative activities.  The situation today is one where R&D activities are located 
overseas increasingly to augment and acquire new assets. MNEs undertake more 
strategic innovation abroad, with the intention of acquiring and internalising 
technological spillovers that are host location-specific. Thus there is increasing 
specialization of R&D activities between subsidiaries in different locations to take 
advantage of specialized immobile knowledge assets. This is reflected in the growing 
geographical spread of MNE’s centres of excellence (see for example Holm and 
Pedersen 2000), the growing phenomenon of reverse technology transfer (e.g. 
Håkanson and Nobel 2000, Håkanson and Nobel 2001, Zhou and Frost 2003),  and 
the adoption of new R&D organizational structures where foreign subsidiaries 
contribute as much as the home location of the MNE to the creation of new 
technological assets (e.g. Chiesa 1996a, Gassmann and von Zedtwitz 1999, von 
Zedtwitz and Gassmann 2002). MNEs are moving away from a ‘centralised hub’ to a 
multi-hub ‘integrated network’. 
However, it is one thing to implement a dispersed R&D structure; it is quite another to 
achieve successful and efficient coordination, since personnel and management do not 
always adapt to these new structures, as they require inordinate amounts of 
coordination as well as new knowledge-exchange and networking abilities. There are 
a number of barriers to the internal knowledge diffusion process connected to inter-
units geographical, organizational and technological distance and also to the 
motivational disposition of both the sender and the receiver units (see Gupta and 
Govindarajan 2000, Kogut and Zander 1993, Szulanski 1996). Thus if firms want to 
reap the benefits of a geographically dispersed R&D organization, they must ensure 
that knowledge generated in different units of the network is transferred to the rest of 
the organisation and this requires the adoption of new mechanisms for the 
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dissemination and integration of both explicit and tacit knowledge. In other words, 
firms experiences a certain amount of organizational inertia, in that despite new 
structure being implemented, knowledge flows and coordination de facto continue to 
sub-optimally follow the same patterns associated with the old structure. 
This paper aims to analyse what are the managerial challenges in achieving 
knowledge transfer inside multi-hub integrated R&D network organizations and in 
overcoming organizational inertia. In particular this study assesses what are the 
organizational and socialization mechanisms in the R&D organization in the internal 
knowledge diffusion and integration process. Knowledge resides in individuals and 
knowledge flows within the firm take place in social communities, i.e. in networks of 
relationships among organizational members. The literature on social capital (e.g. 
Hansen 1999, Tsai and Ghoshal 1998) has highlighted the importance of the creation 
of social structures in the diffusion of knowledge within and across organizational 
units. Research has shown that the use of socialisation mechanisms is positively 
related to knowledge flows within the MNE (Gupta and Govindarajan 2000). 
Particularly in the R&D context the adoption of socialisation mechanisms can 
facilitate the transfer of knowledge, especially in the tacit form, through the creation 
and maintenance of personal relationships.  
The paper is organized as follows. Section 2 discusses the theoretical framework 
focusing on the concept of organizational inertia and on the internal barriers to inter-
unit knowledge flows. Section 3 outlines the methodology of the study. Section 4 
describes the main distribution of the innovation activities and R&D organisation 
across geographically dispersed units. Section 5 reports the empirical findings of the 
study on mechanisms employed to ensure that technical knowledge crosses both 
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geographical and disciplinary boundaries, and on the role of socialization mechanisms 
in this process. The final section concludes the paper.  
ORGANISATIONAL INERTIA AND THE CHALLENGES OF THE MULTI-HUB 
STRUCTURE  
Traditionally the most strategic and ‘core’ innovation activities were concentrated in 
the central R&D unit in the home country of the MNE. In this model, dubbed the 
‘centralised hub’ (Bartlett 1986), there was only one centre and MNEs relied largely 
on one location, i.e. the home country, as the principal source of their competitive 
advantage. In this organisational setting the flow of knowledge was mainly in one 
direction: from the headquarters, where it was created, to the subsidiaries, where it 
was further developed to adapt products and processes to the local market (see Figure 
1). However during the mid-1980s a different organisational model was proposed to 
take account of the fact that MNEs were facing increasing pressures towards ‘global 
integration and responsiveness to local conditions’ (Bartlett 1986). In this context 
MNEs could not rely only on exploiting internationally the technological assets built 
on home-country competences, but had to source knowledge from each leading 
market and national technology system. As a result the so-called ‘integrated network’ 
(Bartlett 1986) organisational model was proposed. In the integrated R&D network 
structure each R&D unit assumes a leading role in the creation of unique competences 
that can be leveraged by the rest of the organisation (see Figure 2). Within this model, 
the creation of new technologies is not the prerogative of the centre, but rather takes 
place in foreign subsidiaries building on and exploiting host countries’ competitive 
advantage. 
With the shift from centralised to multi-hub structures communication among 
different R&D units is even more crucial as complex sets of formal and informal 
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institutions need to be redesigned and developed. In the integrated network model 
technological upgrading emerges from complex external and internal knowledge 
flows both between subsidiaries and from the centre to the periphery. Thus the firm 
has to move away from the management of a set of dyadic relationships between the 
centre and the foreign R&D unit and adopt a more systemic coordination mechanism 
in order to promote intensive communication flows, both within networks internal to 
the firm, and between external and internal networks.  
ORGANIZATIONAL INERTIA 
However firms show a ‘persistent organizational resistance to architectural change’ 
(Hannan et al. (2002), i.e. they suffer from organisational inertia. Inertia implies a 
lethargy to change, and that a state of affairs continues to be so, unless an exogenous 
force is applied to change it. Inertia implies that firms will prefer to maintain the 
status quo, until a change in circumstances requires the firm to do so. Firms are by 
definition loathe to radical change, and firms will always prefer to maintain the status 
quo if it does not endanger their competitiveness. 
As Hannan and Freeman (1984) explain, structures evolve in response to the 
organisational need to maintain a certain amount of reliability and accountability, and 
in order to achieve these objectives, institutionalisation of routines and standardisation 
of processes is required. However, these characteristics that provide stability also 
result in inertia. The level of inertia is increased when there is a high level of 
complexity, which makes it even more difficult to reorganise.  Organisations marked 
by a high degree of complexity and opacity tend to show higher levels of inertia 
(Hannan et al. 2002).  
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While organisational structures are relatively easy to change – often by fiat by 
headquarters – implementing these changes systemically through an organisation 
often requires fundamental changes in the institutions that make organisational 
structures efficient, and it is here that organisational inertia faces its greatest 
challenges. Major changes that derive from changing the raison d’être of an 
organisation require new institutions, which –especially informal ones -evolve only 
gradually over time. In the case of R&D activities the most significant issues are the 
‘know-who’. Suppliers, professors, private research teams and informal networks of 
like-minded researchers take considerable effort to create, and once developed, have a 
low marginal cost of maintaining.  Such informal institutions, are however, specific to 
particular research areas and specialisations, and are difficult to transfer from one 
organisation to another, and have often taken years to develop. This creates two types 
of problems. First, researchers are not prone to share this knowledge with other 
research teams in other locations, even where they are part of the same MNE. Second, 
it is difficult to shift R&D personnel from one area of specialisation or location to 
another without experiencing a drop in efficiency or employee attrition.  
Firms are path-dependent, and find it costly to break away from existing technological 
routines towards radically new or different concepts. There are additional costs 
involved in switching trajectories which may impede organisational change and 
exacerbate the level of uncertainty and therefore economic risk. Organizational 
structures (and particularly informal and formal institutions between R&D personnel) 
tend to have evolved to address particular kinds of challenges, and the flexibility that 
less complex and less specialised units (say, sales, production, marketing) may be 
able to show are simply not always present in R&D organisations.  
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Organizational inertia is in itself neither a ‘good’ or a ‘bad’ thing. Where stability, 
predictability, replicability and reliability are important, inertia can have positive 
effects, when rapidity of response is required to uncertainty and complex milieu’s, 
inertia may impede change. R&D organizations require a mix of these two 
circumstances, and this requires considerable investment in coordinating and 
achieving knowledge diffusion and integration.  
BARRIERS TO INTER-UNIT KNOWLEDGE FLOWS 
It is often argued that transfer of knowledge within units belonging to the same 
organisation is easier to achieve than is the transfer of knowledge between 
organisations (Grant 1996, Kogut and Zander 1992) and that the main competitive 
advantage of multinationals lies in the possibility of transferring and integrating 
knowledge generated by subsidiaries located in different countries. However, several 
authors have pointed out that knowledge transfer even within organisations is far from 
being an automatic process.  
Internal knowledge diffusion can be impaired by inter-unit technological distance 
within the MNE who have shifted to a differentiated R&D network. Knowledge 
sharing requires that the sender and receiver have a common set of prior knowledge. 
The increased level of technological specialisation and diversification in the R&D 
organisational network may reduce the amount of shared knowledge hindering the 
process of knowledge transfer. In other words, technological specialisation may 
introduce inter-unit differences in ‘absorptive capacity’ (Cohen and Levinthal 1990 p. 
128). As demonstrated by Szulanski (1996) and Gupta and Govindarajan (2000), 
absorptive capacity in the receiving unit is a necessary condition for the successful 
transfer of knowledge. If the increasing level of internal technological specialisation 
can be an obstacle to the diffusion of knowledge it may also represent the main 
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strength of the integrated R&D network structure. Enhancement of the quality of the 
innovation process may derive from the international cross-fertilisation of knowledge 
within individual technologies and/or the recombination of knowledge across related 
technologies (Zander 1999).  
Also, international R&D configurations tend to reflect facilities that have been 
acquired through M&A, long-standing R&D facilities and newly-established ones. In 
other words, there is considerable organisational distance that derives from non-
technological differences. Many of these individual establishments have had little or 
no history of cooperating, and indeed in may instances have been engaged in inter-
unit rivalry under a centralised hub model, or in the case of newly acquired 
operations, have been de jure competitors. Achieving a harmony of inter-facility 
division of labour is all the more difficult because of these inter-unit rivalries. This 
increases the role of headquarters in coordinating and improving lateral 
communications.  
Both organizational and technological distance problems are further exacerbated by 
the fact that in R&D, different aspects require different organisational structures, 
rather than a ‘one-size-fits-all’ approach.  In the case of basic research, personnel tend 
to have very little interaction with the day-to-day operations of the firm. Interactions 
tend to be governed by informal institutions, and organisational structure is loose and 
flexible in order to cope with the complexity. Units tend to be small and very highly 
specialised in very strongly delineated niches, and may even be said to be ‘over-
specialised’. Encouraging cross-fertilization requires overcoming much stronger 
barriers than in any other aspect of value adding activity. At the other extreme, 
development work requires considerable interaction with production and marketing 
activities within the firm, as well as customers. There are often numerous formal 
 9
institutions and routines that have been established, and organisational structure much 
‘tighter’. Development activities can be more easily concentrated in a few locations, 
often close to the primary markets, and can service a variety of different technologies 
and markets.  
Geographical distance also plays an important role. The tacit and firm-specific 
nature of technology means that knowledge spillovers that are the fundamental to 
achieve cross-fertilisation are more efficiently internalised when in close physical 
proximity between the units, or between the individual researchers.  Early studies by 
Allen (1970, 1977) showed that physical proximity affects the likelihood of 
communication among R&D staff within technical functions and between technical 
functions and other functions in a firm. Although these problems have been mitigated 
by developments in ICT, which have facilitated the management and coordination of 
international research networks, geographical distance is still a barrier to the transfer 
of knowledge especially if it is tacit in nature (Howells 1995). Distant R&D units find 
it difficult to communicate because the exchange of their knowledge takes place 
mainly through personal contacts (De Meyer 1993). 
These challenges of geographical distances naturally also reflect different national 
cultures of units as well as organisational cultures. The adoption of a geographically 
distributed R&D organization implies the existence of a strong cultural heterogeneity 
which creates barriers to knowledge sharing. The lack of a common culture and 
greater autonomy may introduce motivational barriers in the subsidiary to transfer 
technology within the organisation. As Cyert (1995) points out, there is the possibility 
that affiliates might be reluctant to transfer knowledge to other units of the MNE 
because they lose an ‘information monopoly’ within the company and their status as a 
‘centre of competence’ in a specific area. The motivational element can be particular 
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important in determining knowledge transfer from units that have been recently 
acquired, although with time this effect can fade way. 
PROMOTING INTER-UNIT KNOWLEDGE FLOWS 
One of the means to achieve knowledge transfer and integration is the creation of a 
common culture and convergence towards the same set of values, what Gupta and 
Govindarajan (2000) define as socialization mechanisms, i.e. job rotations among 
subsidiaries and between subsidiaries and headquarters. Hedlund (1986) recognized 
the importance of human resource management in the ‘heterarchical’ model: “In order 
for internalisation of norms to take place, a lot of rotation of personnel and 
international travel and postings are necessary…Advances in information technology 
may help the formation of the nervous system of the firm, but this will not be enough 
for building internal cultures” (p. 29, emphasis added).  
Particularly in the R&D context the adoption of socialization mechanisms are crucial 
in facilitating technology transfer because they help to establish inter-personal 
relationships through which less codified form of knowledge can be shared. Cross-
borders research projects, temporary international assignments to other R&D units, 
site rotations of researchers, short-term visits, exchange programs are some of the 
practices used to promote the formation of social ties among R&D personnel working 
in distant laboratories (Bartlett and Ghoshal 1990, Chiesa and Manzini 1996, De 
Meyer 1993, Persaud et al. 2001, Teigland et al. 2000, Westney 1993, Zhou and Frost 
2003). What is most important is that personal relationships tend to last also once the 
scientists stop working together or they return back to their original R&D facility 
(Agrawal et al. 2003). As argued by Zhou and Frost (2003) international project 
teams create a common understanding and help to identify ‘who knows what’ in other 
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R&D units. Similar results can be reached through temporary assignments of R&D 
personnel to other R&D facilities. These socialization mechanisms can help achieving 
inter-unit knowledge transfer and knowledge integration across geographic and 
disciplinary boundaries, as well as contributing in reducing organizational distance.  
RESEARCH METHOD 
The exploratory nature of the questions addressed in this paper makes a case study 
approach based on data collection the most appropriate research strategy. Data were 
collected through 24 face-to-face semi-structured interviews with R&D managers and 
scientists in six of the largest European pharmaceutical companies (some descriptive 
statistics of the interviewed companies are reported in Table 1). These pharmaceutical 
companies provide a particularly interesting context in which to investigate our 
research questions for three principal reasons. First European MNEs in this industry 
carry out an increasing proportion of their R&D activities in the US in order to 
acquire specialised capabilities in biotechnology (Allansdottir et al. 2002, Reger 
2000, Senker 1998, Shan and Song 1997, Sharp 1999). Second, the pharmaceutical 
industry has moved from being a trial-and-error drug discovery process to becoming a 
more science-based deductive method of search (Arora and Gambardella 1994) which 
has led to new divisions of labour and new R&D organisation both across functions 
(Chiesa 1996b) and across borders (see Appendix for a description of the drug 
discovery process and its latest development). Finally, this sector has recently 
undergone a process of consolidation that has been characterised by complex mergers 
and acquisitions (M&A) among large incumbents firms. In this context of 
organisational distance between R&D units that previously belonged to competing 
companies and lack of interpersonal relationships among R&D personnel, building a 
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better understanding of how knowledge diffusion and integration is achieved, is 
critically important.  
*************** INSERT TABLE 1 ****************** 
Between two to six interviews of one and half hours were carried out in each 
company between June 2002 and April 2003. The interviews were based on two 
separate but overlapping sets of questions for the managers and the scientists. This 
allowed corroborating the validity of the data that might otherwise be biased 
depending on the position of the individuals within the organisation. The interviews 
were transcribed and the data analyzed for commonalties based on the research 
question. Some excerpts of the interviews are reported in the empirical section of the 
paper. 
THE R&D ORGANIZATIONAL STRUCTURE 
Before discussing in more details the managerial challenges faced by these companies 
and their adopted strategies to overcome them, in this section we analyse their R&D 
organizational structure and its evolution over time.  
As can be seen from Table 2, all the companies in the sample have an R&D presence 
in several continents with foreign research facilities actively engaged in drug 
discovery activities in one or more therapeutic areas. The therapeutic alignment of 
each location is determined by the pre-existing capabilities of the research units, 
especially for those companies that have recently merged (e.g. GSK, Aventis and 
AstraZeneca) and by the host-country specialization.1  
************** INSERT TABLE 2 ************* 
                                                 
1 Note that across all companies drug discovery in oncology and immunology is mainly concentrated in 
the US facilities. This is in line with the US specialization in bio/gene technologies. 
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From an organizational point of view we found two important results. First, across all 
companies drug discovery activities are organized differently from the drug 
development phases. The innovative efforts in the drug discovery phase are carried 
out in an integrated network of research facilities, while the organisational structure 
of the development activities is organised as a polycentric decentralised structure 
characterised by a lower level of inter-unit interaction. Second, we identified two 
different integrated network structures in the drug discovery phase: one represented in 
Figure 3, which more closely reflects the ideal integrated network organization (see 
Figure 2) and which does not represent a radical change from the pre-existing 
organizational configuration (see Figure 7), and another, shown in Figure 5, adopted 
by Glaxo Smith Kline and Aventis, which represents a more innovative response to 
the challenges and costs of the integrated network structure.  
************INSERT FIGURE 3 ********** 
In Novartis, Roche, Schering and AstraZeneca all the activities connecting to the 
identification and optimization of the compound are carried out in geographically 
dispersed research units specialized on specific therapeutic areas (with a minimum of 
three for the case of Schering to a maximum of eight for AstraZeneca). In each centre 
a critical mass of scientists and technicians specialised in a set of targets for a disease 
area are brought together, facilitating personal interaction and the exchange of tacit 
knowledge. The organisation of research activities according to therapeutic areas has 
been made possible by the new heuristic in drug discovery (see Appendix). This more 
systematic method has allowed scientists to focus on specific groups of targets in 
particular centres of expertise. This allows the firm to access multiple external 
knowledge sources from centres of excellence around the world and/or internal 
knowledge sources from research units with a strong technological background within 
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the organisation. At the same time the firm’s innovative efforts are enhanced by 
greater interaction among researchers, which is necessary for succeeding in tasks that 
rely heavily on tacit abilities and trial-and-error activities. The following comments 
illustrate this point:  
‘It is important and easy to have pharmacology and chemistry in the same location, 
because the work of these two departments is very much interconnected’.  
‘We prefer to have a project in one site within the domain of the project from synthesis, 
to analytics and screening. All these functions are more easily and efficiently done in 
one site’. 
This network structure is characterised not only by very intense intra-unit but also 
inter-units knowledge flows especially when there is more than one research centre 
specialised in the same therapeutic area.  
Development activities, instead, tend to be concentrated in a few locations in order to 
achieve critical mass and economies of scale. As explained by an R&D manager:  
“The studies associated with the discovery of a compound are quite small. They can be 
located in one place, but studies associated with the development of a compound are 
big and you need a large organization to cope with these studies” 
Similarly a scientist commented:  
“In development, economies of scale is the biggest benefit. But in research, size does 
not seem to help. You want small group agile not tied up with bureaucracy, thinking 
innovatively, making use of the cultural differences. In research smaller is better” 
These development units are mainly located in the home country and the US with the 
aim of being near the largest markets and the regulatory authorities. They usually 
confine themselves to developing the results from research units located in the same 
region and are coordinated by a global development centre. The degree of interaction 
among the development centres is not as intense as among the research network 
although they frequently carry out studies for other development centres whenever 
these have problems of insufficient capacity.  
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***********INSERT FIGURE 4*************** 
Roche has organized its R&D activity in four research sites, two in the US (Palo Alto, 
California, and Nutley, New Jersey), one in Switzerland and one in Germany, where 
all the drug discovery functions are carried out up to the pre-clinical development 
phase. Pre-clinical and clinical studies are instead concentrated only in two centres, 
one in Europe and one in the US, to support the submission of drug to the local health 
authorities (see Figure 4). Similarly in Novartis, established by a merger between 
Sandoz and Ciba-Geigy in 1997, all the phases of the drug discovery process up to the 
pre-clinical stage are performed in each of the research sites. The compound is further 
developed in Basel, the US and the UK. Likewise in Schering since 2001 there have 
been five Research Business Areas (in vivo diagnostic, 
Neurology/Immunology/Cardiovascular, Dermatology, Gender Health Care and 
Oncology) which are attached to three research sites (Berlin, Richmond, US, and 
Mubara, Japan). The activity of each research site is supported by three regional 
research centres in Europe, Japan and the US. In AstraZeneca, the company resulting 
from a merger between Astra and Zeneca in 1999, each site is a fully-fledged R&D 
facility engaged in activities which range from early discovery to life-cycle 
management in a particular therapeutic area.  
If this organizational structure allows these companies to access knowledge from the 
US universities and to make contacts with US biotech firms (as outlined by an R&D 
manager), managing and coordinating the network of integrated laboratories is 
extremely costly because you have to move key project members from one site to 
another. In order to reduce these costs, GSK and Aventis have concentrated certain 
phases of the drug discovery process in centres of excellence and have implemented a 
different network structure shown in Figure 5.  
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************** INSERT FIGURE 5 ******************* 
As a result, inside the integrated network structure there are small, autonomous, and 
flexible units able to take decisions more rapidly and freely as regards the allocation 
of resources and the establishment of collaborations with external partners. At the 
same time they are ‘almost set up like independent operations if they were small 
biotechnology companies’ (as an R&D manager explained) and they compete for the 
resources that are distributed according to how close their molecules are to the market 
and how well they have performed. However, as we will discuss in the next section, 
this structure can lead to inefficiency in terms of lack of inter-unit communication and 
knowledge fertilization.  
Since the merger of Glaxo Wellcome and Smith Kline Beecham in 2000, the early 
phase of their discovery process has become a global function located primarily in the 
UK, in the US and in Italy (see Figures 6). Once molecules have been identified and 
optimised they are passed over to the Centres of Excellence of Drug Discovery 
(CEDDs) which are aligned by therapeutic areas; and chemists and biologists, experts 
in the disease in question, can work closely to bring the compound to the proof of 
concept phase. Once the compound has reached this stage, it is transferred to global 
development functions where it undergoes further clinical tests. 
****************INSERT FIGURE 6 ************** 
Similarly, in Aventis there are three drug-discovery sites (Paris, Frankfurt and 
Bridgewater, US) that are set up as entrepreneurial units and compete on a global 
basis for resources. Each site has responsibilities from the early phase of a project up 
to the proof of concept phase, but the project team gets support from the so-called 
Global Functions of Lead Generation and Lead Optimisation. There is a Global Drug 
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Development centre in Bridgewater, from where all clinical development activities 
subsequent to the proof of concept stage are coordinated. Clinical trials are carried out 
all over the world, monitored by regional development centres in Paris for Europe, in 
Tokyo for Japan, in Bridgewater for the US. This R&D organisation has been in place 
since the creation of Aventis, which resulted from the merger of Hoechst and Rhone-
Poulenc in 2000. 
The existing R&D network organizations have evolved from a hub-structure where 
each centre had the responsibility to pursue research in certain therapeutic areas under 
the coordination of the headquarters (see Figure 7). Each centre was organised as a 
completely self-sufficient R&D unit, where most of the phases of the drug discovery 
and development process were carried out. Each R&D centre was fairly independent 
and there was an element of competition among the different units. In general 
communication among the different sites was not very intense and cross-border team 
projects were not often implemented, as shown by the following comments of both 
scientists and R&D managers:  
‘Things were worked almost exclusively in each site. Each location was self-contained, 
they had all the resources to carry out all the function that a project required. There 
were no cross-national teams.’ 
‘The research sites were much more independent of each other. They had their own 
budget and the head of each site was responsible for everything. There was a certain 
level of competition between different sites, we did not work very effectively together 
as a group’. 
‘Now people here talk to people there which was not the case before, because they 
were in competition with each other. The competition emerged when we had to decide 
who had to work on a specific target. Now we have common projects which do not 
contribute to a specific research centre’s productivity but they contribute to the whole 
organization’ 
As can be seen by comparing Figure 3 and 7, the integrated network structure 
implemented by Novartis, Roche, AstraZeneca and Schering represents a ‘natural’ 
evolution from the previous hub-structure although in the old configuration there was 
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not geographical and organizational separation between the research and development 
functions. GSK and Aventis’s organizational structure entails a more radical change 
from the pre-existing structure, which however reflects a trend towards re-
centralisation and consolidation in few and small leading research centres to reduce 
costs, increase flexibility and productivity through inter-unit competition (a trend 
identified also by Gassmann and von Zedtwitz 1999).   
Although there is a movement away from a centralised and co-located organizational 
structure towards an internationally distributed network there is same evidence of 
organizational inertia.  In other words, although the motto of one of these companies 
is ‘think global act global’ and there is a managerial effort in using resources 
globally, scientists appear to build their innovative efforts using pre-existing routines 
which have been developed in the pre-existing organizational structure. This is also 
reflected in the way they exploit their personal network of relationship inside the 
company. As noted by a senior researcher:  
‘Although we have an electronic archive with lists of expertise and contacts, I rely on 
my personal contacts. You can store as much information as you want, but it only 
becomes knowledge if you know the other person’.  
EVIDENCE OF GEOGRAPHICAL, TECHNOLOGICAL, ORGANIZATIONAL 
DISTANCE AND INTER-UNIT RIVALRY 
The existing organisation of research activities is thus quite complex and involves a 
high degree of lateral communication among geographically dispersed research 
centres that operate in an integrated way during the drug discovery process. The 
complexity of the knowledge diffusion process inside the network derives from the 
fact that knowledge acquired in a particular therapeutic area has to be transmitted not 
only to other units working in the same therapeutic area but also to other therapeutic 
areas where it could be employed. Results from the drug discovery process must also 
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be transferred to the units carrying out development activities. One of the potential 
problems inherent in this structure is thus the lack of integration of knowledge 
produced in geographically distant units which could result in a decrease in the firm’s 
innovation performance and lack of cross-fertilisation of knowledge across different 
therapeutic areas.  
As illustrated in the previous section research and development units are scattered 
around the world thus geographical distance is a common characteristic of both 
types of integrated network organizations. Organizational distance is also a common 
feature of these firms because, as shown in Table 2, most R&D centres were created 
from pre-existing research facilities which used to belong to different companies and 
because drug discovery and development activities are organized separately. Finally, 
there is a high degree of inter-unit technological distance because each centre is 
specialised in a different therapeutic area or in different approaches to a particular 
disease.  
The increased specialisation of knowledge used in investigating specific therapeutic 
targets and, within these, particular methodological approaches2 is the main cause 
behind the high level of inter-unit technological distance, as shown also by the 
comments of a chemist and a toxicologist: 
‘I communicate very rarely with scientists in other locations because the therapeutic 
area I am working on is only located here. I do not have formal contacts with other 
colleagues … other colleagues working in other therapeutic areas have completely 
different structures, different chemistry, we can hardly ever help each other’.  
‘I would use very little the R&D results from other subsidiaries, because our projects 
are very separated, they have different target indications as compared to what we are 
                                                 
2 As pointed out by an R&D manager in the area of oncology: ‘Each site focused on oncology is 
specialised in a particular treatment paradigm: the functional treatment paradigm (i.e. hormones), and 
the anti-angio-genesis paradigm (i.e. we try to block the nutrition of the cancer cells) are investigated in 
Europe, while in the US they are more exploring the use of gene therapy and immunology to fight 
cancer’. 
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doing, so I would not have very much exchange of data, because we do not overlap’ 
(emphasis added). 
In GSK and Aventis’ drug discovery organisation inter-unit technological and 
organizational distances seems to be more severe because of the way the centres of 
excellence have been created. As a GSK R&D manager explained: 
‘The CEDDs are almost like separate companies, they have their own budget, their 
own ways of working. One of the dangers of the CEDDs is that they might end up not 
sharing best practices. The CEDDs have various levels of communication, but it is 
pretty poor, because they have been set up almost like small companies. They are 
almost in competition, they are evaluated based on the value that the particular CEDD 
delivers to the business. In addition people do not move between CEDDs because they 
have expertises in a specific therapeutic area’ (emphasis added). 
The same view was provided by a senior scientist:  
‘The CEDDs are more geographically located and among them there is a minimum 
level of communication, mostly based on personal relationships. Most of the people in 
Upper Marion do not know the people in North Carolina because they used to belong 
to different companies.’ 
The inter-unit rivalry strategically introduced in order to achieve ‘biotechnology 
style mind sets’ has created barriers in the internal knowledge diffusion and 
integration process. Researchers working in distant locations do not communicate not 
only because they do not know each other or because they are working in very 
different areas but also because there are in competition with each other (the absence 
of arrows in Figures 5 and 6 among different centres excellence reflects the lack of 
communication among these units). 
IMPLEMENTED SOLUTIONS: ORGANIZATIONAL AND SOCIAL MECHANISMS 
There are some organizational measures in place to reduce geographical and cross-
disciplinary boundaries. Projects to develop a drug are carried out by people working 
across different functions. These firms organize their research projects according to a 
certain disease area rather than by a geographical location, which implies that 
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people from different research sites might work together in cross-border team 
projects.  
In GSK the main organizational knowledge integrator across CEDDs are the global 
functions (discovery and genetic research and drug development). As shown in Figure 
6, the CEDDs are all in contact with both the research units involved with the 
identification and optimization of the compound, as well as the development units 
running the clinical trials. As explained by a senior scientist in drug development: 
‘Because we are a global function and the CEDDs are six centre of excellence around 
the world each doing a different thing, if we are not careful they can go in different 
directions. By working with the global functions it means that if we develop a 
technology that it is useful to the CEDDs we can make it available to all the CEDDs. 
Or if we see that in one location a CEDD develops a technology that can be useful to us 
(or to other CEDDs), we can help channel that technology because we are in contact 
with all the CEDDs.’ 
In most companies there are also specific task force of experts in particular target 
family, such as kinesis or proteases, or inflammatory targets with applicability to all 
disease areas (called platforms in Aventis). These experts support the projects teams 
located in different research units by collecting all the information in-house about 
these targets and also by following the development in these areas outside the firm. 
The task of this group of experts is to integrate and diffuse the knowledge across 
different locations and therapeutic areas. 
An organizational measure adopted by one company is cross-disciplinary project 
proposal review boards. These boards are formed by peer reviewers coming from 
different areas and from different R&D units that can facilitate the cross-fertilization 
of knowledge across therapeutic areas and locations.  
However to avoid compartmentalisation along disciplines firms also try to increase 
the level of communication among scientists working on different therapeutic areas 
and in distant locations using socialization mechanisms. Cross-border and cross-
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disciplinary projects are frequently employed. Due to the organisational setting of the 
R&D function it is often the case that researchers from different locations are 
involved at different stages in a drug discovery project. However cross-border team 
projects are seen more as an unavoidable consequence of the R&D organisation than 
as a strategic means for increasing knowledge diffusion inside a geographically 
dispersed R&D network. This clearly emerges from the comments of R&D managers: 
‘The one-location team is the preferable model because it is the more efficient, but the 
reality of our organisation is that most of our teams have members based in at least two 
countries and some of them three. My personal view is that if you can have one 
location team you are going to be better off, if you can have all sitting in one corridor is 
going to work better. But this is [now] the exception to the rule’. 
‘I think that the best solution is to have everybody in the same location. But it is good 
to have diversity, but it is very difficult to communicate especially with Japanese 
because of language barriers and the cultural differences. This is also a problem in the 
US’ 
Temporary assignments appear to be the preferred socialisation mechanism when 
firms aim to achieve transfers of know-how from the discovery to the development 
phase. This handover from research to development is ‘very tricky’ (as defined by an 
R&D manager) because there is a departmental change. ‘Research tries to ensure that 
the product survives up to the point it is passed over to the development phase. In 
development people would not trust what has been in research’. To overcome the 
inter-unit attrition researchers from the development function work closely with the 
discovery team for up to a year before the compound has been identified.  
‘What we would often do is to have a period of secondment where a medicinal research 
chemist [from research] will spend sometimes in process chemistry [in the drug 
development phase]. And sometimes the process research chemist will follow the 
compound and spend some time in secondment at the manufacturing site chemistry [in 
the drug production stage]. We try to optimize the information and the knowledge flow 
but it is also good because they gain experience and start seeing things in a different 
way’ 
‘The way we approach the hand-over from research to development is that the people 
will work very closely with the discovery people up to one year before the compound 
is finally identified. We use secondments and short-term assignments (from three to six 
months) we have people who travel a lot in terms of maintaining relationships’ 
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Longer term assignments (from 6 months to one year) are also used, although to a 
lesser extent. They accomplish three purposes: inter-unit knowledge transfer, 
identifying ‘who knows what’ in other locations and reducing inter-unit attrition. 
Indeed increasing organizational proximity through the creation of personal 
relationships between researchers working in distant R&D facilities was the main 
motivation behind an exchange programme put in place by one of the companies: 
‘Historically, communication and cooperation between European and US sites has been 
difficult due to the different research philosophies. During the mid 1990s there was 
more competition than cooperation with them. During that time it was even difficult to 
exchange knowledge. To overcome cultural differences and to increase a common 
understanding among colleagues from different continents, staff exchange programs 
have been established. Now, after the first exchange of staff, things are improving … 
People taking part in the exchange programme should be the bridge between the two 
sites. It is important to know people, it is much easier to deal with them if you have 
worked with them’ (emphasis added). 
Transfers of know-how between research units are more difficult to achieve especially 
when they are specialised in different therapeutic areas. Companies try to stimulate 
interdisciplinary knowledge flows by promoting and officially supporting 
communities of scientists and technology councils. Technology councils are set up to 
discuss problems faced in using particular technologies, such as those used in 
combinatorial chemistry or high through-put screening. The members of these 
communities interact regularly through intranet, meetings and formal workshops. 
These councils provide a forum where individuals can share best practice and some of 
the challenges they face in using a particular technology or dealing with critical tasks 
or topic in a particular discipline.  
CONCLUSIONS  
MNEs have evolved in a short span of time from simple centralised structures to 
complex modes of organisation such as the multi-hub structure, in response to the 
processes of globalization. These structures have allowed the MNE to take advantage 
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of dispersed sources of knowledge and to exploit synergies across the different R&D 
centres through cross-border innovation projects. Furthermore, different structures are 
used for research activities than for development activities, reflecting the different 
character of the two aspects of innovation. 
However, as this paper highlights, implementing changes in organisational structures 
– particularly for R&D activities – to more efficiently exploit resources and 
capabilities on a global basis poses a variety of managerial challenges.  Some of these 
challenges are more general, in the sense that they apply to all aspects of value adding 
activities within a globally integrated MNE, such as the complexities of promoting 
and integrating knowledge flows in the face of inter-unit geographical, organizational 
and technological distance. As innovation activities are primarily about the creation 
and diffusion of knowledge, much of which is tacit and non-codifiable, a higher 
degree of lateral communication among dispersed research centres is required. This is 
achieved through a variety of organizational and socialization mechanisms, some of 
which we have discussed here. 
In addition though, inter-unit, inter-disciplinary and intra-disciplinary rivalries – some 
of which have been purposely created to promote innovativeness through 
competition- act also as a barrier to achieving greater cross-fertilization and the 
integration of knowledge. Some of these derive from the nature of research activities, 
and the difficulties inherent in promoting greater interaction between scientists 
engaged in focused research within highly specialised disciplines. However, others 
derive from the absence of central coordinating mechanism that a ‘traditional’ 
headquarters operation may have provided in a centralised hub scenario, which might 
perform the function of an ‘honest broker’.  
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Thus, while multi-hub structures have undoubted benefits, they have also generated 
new costs, particularly in terms of creating unbiased and transparent means to 
promote lateral communications both between centres of excellence as well as 
geographically dispersed units. To be certain, some of this simply represents 
organizational inertia – formal and informal institutions that define the nature and 
direction of interaction within a new structure take considerable time to be refined to 
achieve optimal efficiencies. Nonetheless, the evidence presented here points to the 
continued- if not greater- investment in human, managerial and financial resources to 
promote knowledge integration within a geographically and technologically dispersed 
R&D structure. 
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APPENDIX 
RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRY 
The drug discovery and the development process can be divided in six stages (see 
figure A1). The first three stages comprise the drug discovery phase, which aims to 
identify new compounds; and the remainder of the process comprises the 
development phase, when compounds are tested to assess their efficacy and 
tolerability. The division between research and development is not clear-cut and 
certain companies classify under research part of the clinical development up to the 
proof of concept.  
Figure A1. The drug discovery process 
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Reiss and Hinze 2000). Traditionally the discovery of a new compound was the result 
of a trial-and-error process during which thousands of compounds were screened in 
order to find one with a specific biological profile, because in general the ‘mechanism 
of action’ of a compound was not clearly understood. This process required huge 
laboratories to conduct large-scale screening, and extensive financial, human and 
technological resources. During the 1990s the introduction of what are known as 
enabling technologies, such as high through-put screening, combinatorial chemistry, 
bio-informatics, and scientific advances in biomedical sciences have completely 
transformed the experimental design and the drug discovery process. The discovery of 
a drug is now the result of a science-deductive method and researchers know which 
biochemical and molecular pathways they want to block or stimulate.  
As argued by Chiesa (1996b) the use of new technologies has reduced both the time 
needed to test potential active substances, and the number of researchers required. As 
a result there have been important changes in the organisation and management of the 
R&D function. In essence the size of the experimental unit has been reduced and the 
degree of knowledge specialisation has increased, as has as the number of relevant 
scientific disciplines. In addition the new technological paradigm in drug discovery 
has reduced the importance of tacit and context-specific knowledge in certain phases 
of this process. However the development of a drug still requires large amounts of 
human and financial resources and its efficiency relies on the achievement of a critical 
mass to carry out highly standardised large-scale activities.  
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 Figure 1 The centralised hub R&D structure  
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Figure 3 The integrated network structure in drug-discovery and development 
 
Figure 4 Roche’s R&D organization 
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Figure 5 Integrated network structure with centres of excellence for drug discovery 
 
Figure 6 Glaxo Smith Kline R&D organizational structure 
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 Figure 7 The R&D hub-structure  
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 Table 1 Description of the interviewed companies  
Company name 
Corporate 
headquarters 
2002 Pharmaceutical 
revenues in $ Rank 
No. of Employees 
in R&D1
2002 R&D 
expenditure in $1 Rank 
No. of interviews 
conducted 
AstraZeneca  London 17,841 4 11,000 3,069 4 5
Aventis        
        
       
        
        
Strasburg 16,639 6 5,600 3,235 5 4
GlaxoSmithKline
 
London 27,060 2 15,000 4,108 2 5
Novartis Basel 13,547 8 3,000 2,799 6 2
Roche Basel 9,355 13 5,030 2,746 7 3
Schering Berlin 3,074 19 1,200 869 19 5
Source: Revenues, R&D expenditures and ranking data are from the Contract Pharma Ranking of top 20 pharmaceutical companies (www.contractpharma.com). 
1 Not all R&D employees and expenditure are in the pharmaceutical business of these companies. 
 Table 2 Geographical distribution of research centres and their specialisation 
Company Previously part of  Company Therapeutic Areas 
Zeneca Alderley, UK Infection, Oncology, Inflammation
Zeneca Charnwood, UK Respiratory, Inflammation 
Astra Mölndal, Sweden Neurology, Respiratory Diseases, Inflammation
Astra Gothenburg, Sweden Cardiovascular, Gastrointestinal 
Astra Södertälje, Sweden Pain control, Central Nervous System
Astra Lund, Sweden Respiratory 
Zeneca Wilmington, Delaware, US Central Nervous System
Astra 
Zeneca 
New Boston, US Oncology, Infection 
Hoechst Bridgewater, New Jersey, US Respiratory Diseases, Rheumatoid Arthritis, Central Nervous System, 
Rhône Poulenc  Paris, France Alzheimer’s and Parkinson’s Diseases, Infectious Diseases, Oncology Aventis 
Hoechst Frankfurt, Germany Cardiovascular Diseases, Metabolic Diseases, Osteo-arthritis
Smith Kline Beecham Upper Merion, Philadelphia, US Cardiovascular, Urogenital, Microbial, Oncology
Glaxo Welcome Research Triangle Park, North Carolina, Metabolic and Antiviral
Glaxo Welcome Stevenage, UK Neurology, Respiratory Diseases, InflammationGSK 
Glaxo Welcome Verona, Italy Psychiatry, Neurology 
Sandoz Tsukuba, Japan Oncology, Arthritis
New Cambridge Massachusetts, US Cardiovascular diseases, Metabolism, Infectious diseases.
Sandoz (since 1964) East Hanover, New Jersey, US Oncology, Arthritis, Functional Genomic
Sandoz Vienna, Austria Dermatology, Immunology
Sandoz and Ciba- Basel, Switzerland Nervous System, Transplantation, Oncology, Arthritis/bone, Functional 
Novartis 
Ciba-Geigy Horsham, U K Respiratory, Chronic Pain
Acquired in 1994 Palo Alto, California, US  
Central Nervous System, Inflammatory Diseases/Bone, Genitourinary 
Diseases, Viral Diseases 
Nutley, New Jersey, US Metabolic Disorders, Oncology, Vascular Diseases
Basel, Switzerland Metabolic Disorders, Central Nervous System, Vascular Diseases 
Roche1
Penzberg, Germany Oncology 
Richmond, California, US Neurology, Immunology, Cardiovascular, Oncology
Berlin, Germany In Vivo Diagnostic, Radio Pharmaceuticals, Neurology, Immunology, Schering  
Acquired in 2000 Mobara, Japan Oncology, Neurology
1 Although Roche has financial control over Genentech, this company cannot be considered as a Roche subsidiary. So far, Roche has an ‘opt-in right’ for co-developing compounds discovered 
by Genentech from phase 2 or 3 of clinical development 
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